公司概况 - 公司是一家专注于开发新型癌症治疗药物的商业阶段制药公司[341] 产品销售情况 - 公司的主要产品XPOVIO在2023年的净产品收入为1.12亿美元，总收入为1.46亿美元[342] 财务表现 - 2023年公司的净亏损为1.43亿美元，较2022年的净亏损1.65亿美元有所减少[347] - 2023年许可和其他收入较2022年减少260.7万美元，主要是由于与Antengene的里程碑相关收入和版税收入减少[348] - 2023年研发费用为138,750千美元，较2022年减少了7%，主要是由于人员成本和股权补偿的减少[350] - 2023年销售、一般和管理费用为131,881千美元，较2022年减少了9%，主要是由于股权补偿和咨询费用的减少[351] - 2023年其他费用净额为-13,236千美元，较2022年减少了42%，主要是由于投资收入增加[353] 资金状况 - 我们预计到2023年12月31日的现金、现金等价物和投资将足以支持我们当前的运营计划和资本支出需求，至少可以维持12个月[361] - 我们在2023年底的现金、现金等价物和投资总额为1.914亿美元[362] 市场风险 - 我们的主要市场风险是与美国利率水平的变化相关的利率敏感性[362]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-393 ...

Second Quarter 2023 Financial Results & Business Update On Today's Call Elhan Webb, CFA, Senior Vice President, Investor Relations Richard Paulson, President and Chief Executive Officer • Commercial Highlights • Closing Remarks Richard Paulson, President and Chief Executive Officer This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2023 total rev ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Colleen Kusy - Baird Nicole Gabreski - Piper Sandler Brian Abrams - RBC Capital Markets Operator Good m ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning. My name is ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State or other jurisdic ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank Maurice Raycroft - Jefferies Nicole Gabreski - Piper Sandler & Co. Michael Ulz - Morgan Stanley Edward White - H.C. Wainwright & Co. Eric ...